Shield Therapeutics (LSE:STX) Revenue : £6.19 Mil (TTM As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Revenue?

Shield Therapeutics's revenue for the six months ended in Jun. 2023 was £4.33 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was £6.19 Mil. Shield Therapeutics's Revenue per Share for the six months ended in Jun. 2023 was £0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £0.01.

Warning Sign:

Shield Therapeutics PLC revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Shield Therapeutics was -23.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 46.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 9 years, Shield Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 142.90% per year. The lowest was -58.60% per year. And the median was 36.40% per year.

Shield Therapeutics Revenue Historical Data

The historical data trend for Shield Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Revenue Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Revenue

Get a 7-Day Free Trial

11.88

0.72

10.39

1.52

4.47

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Revenue	Get a 7-Day Free Trial													0.48	1.04	2.61	1.85	4.33

Competitive Comparison of Shield Therapeutics's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Revenue falls into.

Shield Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £6.19 Mil.

Shield Therapeutics (LSE:STX) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Shield Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.